SCHEMBL21974038

SCHEMBL21974038

CCCCCCc1cccc(Cl)c1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 1/20 0.49
TYR P14679 1/20 0.46
BID P55957 3/20 0.45
MCL1 Q07820 3/20 0.45
PPARA Q07869 3/20 0.45
BCL2L1 Q07817 2/20 0.45
BAK1 Q16611 2/20 0.45
KAT8 Q9H7Z6 2/20 0.45
PPARG P37231 2/20 0.45
EP300 Q09472 1/20 0.45
KAT2A Q92830 1/20 0.45
KAT2B Q92831 1/20 0.45
KAT5 Q92993 1/20 0.45
SAE1 Q9UBE0 1/20 0.45
KCNH2 Q12809 2/20 0.44
ALOX5 P09917 1/20 0.44
PTGS2 P35354 1/20 0.44
NR1H2 P55055 1/20 0.41
NR1H3 Q13133 1/20 0.41
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8094335 0.92 ALDH1A1 (0.42) LIPGALOX5PTGS2SMN1; SMN2
SCHEMBL8094251 0.84 ALDH1A1 (0.45)
SCHEMBL27388764 0.83 TYR (0.51) LIPGTYRBIDMCL1BCL2L1
SCHEMBL5701276 0.83 TAAR1 (0.55) LIPGBIDMCL1PPARABCL2L1
SCHEMBL28253265 0.83 TAAR1 (0.55) LIPGBIDMCL1PPARABCL2L1
SCHEMBL27777916 0.83 TYR (0.51) LIPGTYRBIDMCL1BCL2L1
SCHEMBL28006170 0.83 TAAR1 (0.55) LIPGBIDMCL1PPARABCL2L1
SCHEMBL3694247 0.82 LIPG (0.58) LIPGBIDMCL1PPARABCL2L1
SCHEMBL31444780 0.82 LIPG (0.58) LIPGBIDMCL1PPARABCL2L1
SCHEMBL5599139 0.82 LIPG (0.58) LIPGBIDMCL1PPARABCL2L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10941121-B2 Human helicase DDX3 inhibitors as therapeutic agents AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) 2021-03-09 US disclosed
US-20200140398-A1 HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) 2020-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200140398-A1 HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS DDX3X, DDX39B, DDX1 LIPG 3009/4885TYR 4659/4885BID 1477/4885
US-10941121-B2 Human helicase DDX3 inhibitors as therapeutic agents DDX3X, DDX39B, DDX1 LIPG 3009/4885TYR 4659/4885BID 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.